Additionally, we identified 4 new MMVD stage B2 targets (MDM2, ROCK1, RIPK1, and SNAP23) that have been studied in many cardiovascular diseases in human medicine, such as chronic heart failure, atherosclerosis, and diabetic cardiomyopathy. Here, RIPK1 is linked to cardiovascular disorder.